Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC
04:57am, Thursday, 09'th Apr 2026
Cache Advisors LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 43.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exch
Asio Capital LLC Makes New $3.42 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
03:31am, Wednesday, 08'th Apr 2026
Asio Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the undefined quarter, according to its most recent Form 13F filing with the Securities and
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of “Moderate Buy” from Analysts
02:15am, Wednesday, 08'th Apr 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings
Regeneron Wins FDA Nod for Extended Eylea HD Dosing Interval
04:11pm, Monday, 06'th Apr 2026
REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy
01:00pm, Monday, 06'th Apr 2026
Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC
06:22am, Sunday, 05'th Apr 2026
Sovran Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Friday, 03'rd Apr 2026
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
TriNetX arbeitet mit Regeneron zusammen, um Zugang zu anonymisierten elektronischen Patientenakten von 300 Millionen Patienten zu erhalten und damit die Forschung und Produktentwicklung in den Bereichen Biowissenschaften und digitale Gesundheitslösungen voranzutreiben
11:47am, Friday, 03'rd Apr 2026
Regeneron hat die exklusive Möglichkeit, umfangreiche Genom- und Proteom-Datensätze mit dem branchenführenden globalen Netzwerk von TriNetX für elektronische
TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados
09:09am, Friday, 03'rd Apr 2026
- TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados de 300 millones de pacientes e impulsar la investigación y el
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN
03:09am, Friday, 03'rd Apr 2026
Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.8% during the undefined quarter, according to the company in its most recent 13F filing with the
Regeneron a l'opportunité unique de connecter des cohortes de données génomiques et protéomiques à grande échelle au réseau mondial de données de dossiers
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Re
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data
Regeneron says it expects to avoid new US pharma tariffs
02:27pm, Thursday, 02'nd Apr 2026
Drugmaker Regeneron said on Thursday it expects to be excluded from a list of pharmaceutical companies that could face new tariffs from the U.S. government.
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals
